Sarepta Therapeutics (SRPT) stock faces downgrades as it suspends 2025 revenue guidance amid safety concerns for its Duchenne gene therapy. Read more here.

Sarepta Therapeutics stock plummeted Monday after the company said a second patient receiving its gene therapy died from ...

Futures on Wall Street are currently in cautious mode as they await further details on the ongoing hostilities between Israel ...

Key Points The stock market has been remarkably bullish today. Chip stocks are spearheading the gains, and other AI stocks ...

The firm will stop shipping the gene therapy for these patients until a new immunosuppressive regimen is approved for managing acute liver failure.

Swiss pharma giant Roche was 3% lower on the news it had paused the commercial and clinical use of Duchenne muscular dystrophy treatment Elevidys after it was linked to two fatal cases of acute liver ...